Articles tagged with Blood Brain Barrier
Researchers have discovered that drugs targeting brain inflammation can reverse cognitive decline in aged mice by reducing the 'fog' of inflammatory load. This breakthrough offers a potential new treatment for dementia and age-related diseases, with two biomarkers identified to flag people with blood-brain barrier problems.
Researchers used focused ultrasound to target and open areas of the blood-brain barrier in three women with early-stage Alzheimer's disease. The technique successfully opened and closed the barrier within 24 hours, with no adverse effects.
Purdue University scientists have identified key changes in the blood-brain barrier that hinder effective drug delivery to brain tumors. The discovery aims to improve treatment plans and patient outcomes for those with brain metastases from breast, lung, and melanoma.
A study of adolescent and adult athletes found evidence of damage to the brain's protective barrier, without a reported concussion. The researchers detected leaks in the blood-brain barrier using advanced MRI protocol and biomarkers, suggesting that mild impact can still cause significant trauma.
Scientists developed a novel nanotechnology-based approach that successfully delivered checkpoint inhibitors directly to brain tumors, triggering a local immune response and inducing tumor cell death. The treatment has shown promising results in laboratory mice, providing hope for longer survival rates for patients with glioblastoma
A study explores blood-brain barrier leakage in CNS infections, implicating interferon gamma as a major contributor. Interferon gamma disrupts the barrier by initiating a signaling cascade that changes endothelial cell behavior.
Ben-Gurion University researchers develop a human blood-brain barrier chip with stem cells, recreating the natural physiology of the BBB. The chip is used to model neurological disorders such as multiple sclerosis, epilepsy, and Alzheimer's disease.
Researchers created a living blood-brain barrier that functions as in the human body, opening new avenues for studying brain disorders and predicting drug effectiveness. The breakthrough uses induced pluripotent stem cells and Organ-Chips technology.
Researchers are testing a non-invasive procedure that uses low-intensity focused ultrasound to open the blood-brain barrier, allowing treatment to reach the brain and potentially treating neurodegenerative diseases such as Alzheimer's. The clinical trial aims to understand the effectiveness of this method in improving cognitive decline.
Researchers developed a peptide called FRW that binds specifically to endothelial cell junctions in the blood-brain barrier, paving the way for novel diagnostic imaging strategies and therapies. The new technique also reveals differences between the blood-retina and blood-brain barriers.
Researchers at Johns Hopkins Medicine have developed a technique that facilitates precise placement of cancer drugs in the brain using positron emission technology and image-guided drug delivery. This approach shows promising results in improving treatment outcomes for difficult-to-treat brain cancers, such as glioblastoma.
A new study reveals that obesity and insulin resistance can break down the protective blood brain barrier in the brain, leading to problems with learning and memory. Blocking Adora2a receptors in a model of diet-induced obesity maintained barrier function, suggesting that controlling inflammation may prevent cognitive impairment.
Researchers at UBC have discovered a protein called podocalyxin that plays a key role in protecting the brain from harmful blood components during inflammation. The study's findings could lead to the development of new treatments for stroke, epilepsy, and multiple sclerosis by inducing temporary opening of the blood-brain barrier.
Researchers have discovered a biological pathway leading to age-related cognitive decline and found clues to reverse the aging process. Disruptions in the blood-brain barrier allow proteins to leak into the brain, causing havoc and contributing to cognitive decline.
A team of researchers developed a new strategy to overcome the blood-brain barrier's limitations in treating brain cancer. By engineering T cells with a 'homing system' molecule, they enabled these cells to cross the barrier and target tumors effectively.
The xB3 platform efficiently delivers antibodies across the BBB, maintaining systemic pharmacokinetics and improving brain exposure. The platform demonstrates dose-dependent effects in neuropathic pain models, providing a promising treatment for CNS disorders.
Researchers at Wake Forest Institute for Regenerative Medicine have created an advanced brain organoid that closely resembles human brain anatomy. This innovation enables faster drug discovery and screening for neurological conditions, as well as improved understanding of the blood-brain barrier.
Researchers at the University of Kentucky have discovered a potential target for treating epilepsy seizures: cPLA2, an enzyme that contributes to blood-brain barrier dysfunction. Blocking this enzyme may prevent changes in barrier leakage, offering new hope for patients who do not respond well to current medications.
Researchers identified a seizure-triggered pathway that contributes to blood-brain barrier dysfunction in epilepsy. Blocking the activity of an enzyme called cytosolic phospholipase A2 (cPLA2) prevented capillary leakage and associated changes.
Researchers have proposed a new method of treating multiple sclerosis by using the EGFL7 protein to stabilize the blood-brain barrier and prevent immune cell migration. This approach has shown promise in model trials, reducing clinical symptoms and improving treatment outcomes.
Researchers created a detailed molecular atlas of brain blood vessels and the life-essential blood-brain barrier, providing new knowledge on cell functions and disease involvement.
Scientists at IIT fabricated an artificial device reproducing the blood-brain barrier, a structure protecting the central nervous system. The device is composed of artificial and biological components and will be fundamental for studying new therapeutic strategies to overcome the blood-brain barrier.
Researchers conclude that 2-hydroxypropyl-β-cyclodextrin (HPβCD) does not cross the blood-brain barrier, which is crucial for addressing neurological manifestations of NPC1. This finding suggests that direct CNS administration may be necessary to achieve therapeutic efficacy.
Researchers at Brigham and Women's Hospital have developed a system to temporarily loosen the blood-brain barrier using microbubbles, allowing for real-time monitoring and controlled delivery of drugs to the brain. The approach offers improved safety and efficacy control for human clinical trials underway in Canada.
Scientists have developed a 3D all-human reproducible and reliable model of the blood brain barrier, which could pave the way for better, more efficient and reliable tests of drugs to treat brain diseases. The model was created using human cells to simulate the human blood-brain barrier.
Scientists at the University of Würzburg discovered differences in gene expression between embryonic endothelial cells of the central nervous system and other organs, shedding light on the blood-brain barrier's development and maturation. The study also identified transcription factors involved in this process.
Researchers use tiny bubbles and ultrasound to safely open the blood-brain barrier, a heavily guarded system that prevents drug delivery. This breakthrough approach aims to advance next-generation brain therapies without surgery.
Researchers at Brigham and Women's Hospital have developed a new model to mimic the blood-brain barrier, using miniature spheroids that replicate key properties and functions. This innovative approach may advance neuroscience research and expedite the discovery of brain-penetrant drugs for treating diseases.
Researchers developed a lab-based model of the blood-brain barrier defect that causes Allan-Herndon-Dudley Syndrome, a rare congenital disorder. The study may hold promise for treating this syndrome and analyzing other neurological conditions.
Researchers have developed a laboratory model for Allan-Herndon-Dudley syndrome, a rare psychomotor disease that affects brain development. The study uses induced pluripotent stem cell technology to replicate the patient's blood-brain barrier, providing new insights into the disease and potential therapies.
A recent study from Harvard Medical School revealed the surprising role of omega-3 fatty acids in maintaining the blood-brain barrier's impermeable nature. By suppressing transcytosis, these essential fatty acids inhibit the formation of caveolae, a type of vesicle that facilitates molecule transport across cells.
A new research from the National Institutes of Health found that pairing antidepressant amitriptyline with central nervous system drugs enhances drug delivery to the brain. Amitriptyline temporarily inhibits the blood-brain barrier, allowing drugs to enter the brain.
Researchers use bee-venom peptide apamin to develop a novel strategy for delivering medications to the brain. They modified apamin to eliminate toxicity while maintaining its ability to cross the blood-brain barrier, resulting in a promising version called Mini-Ap4.
Researchers found an altered blood-brain barrier and increased intestinal permeability in individuals with autism, supporting the hypothesis that impaired barriers contribute to ASD. The study also revealed reduced expression of barrier-forming cellular components and higher expression of molecules increasing intestinal permeability in...
Researchers developed a microfluidic device that overcomes previous models of the blood-brain barrier, allowing for study of brain inflammation and its link to neurodegenerative conditions. The device was successfully tested with flying colors, paving the way for use in testing new drugs and compounds.
Researchers have developed a technique using microbubbles and ultrasound to deliver drugs directly to the brain, opening the blood-brain barrier. This method shows promise in treating neurodegenerative diseases such as Parkinson's and Alzheimer's.
Researchers review physicochemical properties necessary to penetrate the BBB and conclude a list of properties that can increase the chances of small molecule penetration into the brain. The study emphasizes the importance of retaining the pharmacophore and working it into a structure that emphasizes the presented properties.
A new imaging technique helps identify patients at risk of severe bleeding after stroke treatment by analyzing the extent of blood-brain barrier disruption. This association can inform treating physicians on the risk of bleeding and potentially guide clinical decisions.
A new study published in Radiology found increased blood-brain barrier permeability in people with early Alzheimer's disease. The researchers used contrast-enhanced MRI to identify leakages in the BBB, which could represent a key mechanism in the early stages of the disease.
Researchers at Duke-NUS Medical School have derived a structural model of the Mfsd2a transporter, which could help treat neurological disorders like glioblastoma by bypassing the blood-brain barrier. The study identifies new binding features and provides insight into the transport mechanism of Mfsd2a.
Researchers have found that laser ablation creates a temporary opening in the blood-brain barrier, allowing chemotherapy drugs to pass into the brain. This breakthrough raises hopes for longer treatment options and improved patient outcomes.
Caltech biologists have developed a vector capable of noninvasive delivery of genetic cargo to adult mice brains, holding promise for novel therapeutics. The approach overcomes the blood-brain barrier problem, allowing for efficient gene delivery and targeting specific brain cells.
Gut bacteria break down pomegranate polyphenols to produce urolithins, which are anti-inflammatory and neuroprotective compounds. These compounds reduce A\u00e0 fibrillation levels in vitro and increase lifespan of an Alzheimer's roundworm model.
A study found that long-term aerobic exercise can prevent structural deterioration associated with old age in mice, improving blood-brain barrier function and reducing inflammation. Exercise was particularly beneficial for animals lacking the Apoe gene, a major genetic risk factor for Alzheimer's disease.
A special protein called FoxF2 found in brain's tiny blood vessels affects the development of the blood-brain barrier, a vital protective function that controls substances reaching the brain's nerve cells. Variations in the FoxF2 gene have been linked to an increased risk of stroke in humans.
A team at CHUM Research Centre and University of Montreal has identified a molecule called MCAM that could delay the onset of multiple sclerosis. Blocking this molecule may significantly slow disease progression.
Researchers discovered that an antiviral compound called interferon-lambda can tighten the blood-brain barrier, making it harder for viruses like West Nile to invade the brain. This finding holds promise for treating deadly neurological conditions caused by viral infections.
A team of scientists at San Diego State University has identified a molecular process that allows bacteria to bypass the brain's defenses and cause meningitis. The discovery could lead to new treatments for this deadly disease by controlling the expression of a key protein involved in breaking down the blood-brain barrier.
Researchers discovered that netrin-1 regulates the blood-brain barrier by promoting tight junction proteins. Delivering netrin-1 to mice with MS improved symptoms, highlighting its potential therapeutic benefits.
Researchers from the University of Montreal developed nanorobotic agents that can open the blood-brain barrier, allowing therapeutic molecules to be delivered directly to the brain. The technique involves using magnetic nanoparticles and radio-frequency fields to create a temporary opening in the barrier.
A deficiency in GLUT1 protein worsens Alzheimer's disease symptoms by breaking down blood-brain barrier, while targeting this protein may help prevent the disease progression among those at risk. Researchers found that GLUT1 deficiency led to neuronal dysfunction and behavioral changes.
A USC study reveals that the brain's protective blood barrier becomes leaky with age, starting at the hippocampus, a critical learning and memory center. The findings suggest that brain scans may be able to detect changes in blood vessels before they cause irreversible damage leading to dementia.
A new, physiologically realistic in vitro model of the pediatric blood-brain barrier has been developed and successfully tested. The model, called B3C, mimics the human BBB's structure and function, and has shown promise for studying neurological diseases and testing novel therapies.
Researchers have discovered that blocking blood-brain barrier proteins increases riluzole's effectiveness in treating ALS. The study found improved muscle function and prolonged survival in mice with blocked barriers.
A new study shows that gut microbiota can influence the integrity of the blood-brain barrier, which protects the brain from harmful substances. The findings suggest that alterations to our indigenous microbiota may have far-reaching consequences for the blood-brain barrier function throughout life.
Researchers found that apolipoprotein E-derived therapeutic peptide improved synaptic stability and learning and memory performance after diffuse brain injury. The peptide also protected against brain injury by reducing oxidative stress, suppressing the ERK1/2-Bax mitochondrial apoptotic pathway, and decreasing neuronal death.
Researchers have recreated the complex blood-brain barrier in a laboratory model to study the obstreperous bouncer proteins that protect the brain. The model can be used to test drive difficult ways into the brain and investigate complex phenomena in simple experiments.
A fungal protein has been found to cross the blood-brain barrier, allowing it to infect the brain and cause deadly meningitis. This discovery opens up new avenues for treating brain infections and cancers by targeting the protein or using it as a drug delivery system.
Researchers found that microRNA-155 is responsible for cleaving epithelial cells, creating microscopic gaps that allow toxins to reach the brain. This discovery helps explain diseases like multiple sclerosis and opens a new path for developing therapies that can penetrate the blood-brain barrier.
A team from Harvard Medical School identified a gene, Mfsd2a, that limits the blood-brain barrier's permeability. Blocking its activity could allow selective drug delivery to treat conditions like brain tumors and infections.